Summit signs deal with Eurofarma for Latin American rights to Ridinilazole

This article was originally published here

Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit’s precision antibiotic ridinilazole in development for the treatment of CDI.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply